BrightSpring's Onco360 Selected as National Pharmacy Partner for New Cancer and Rare Disease Drugs

BrightSpring Health Services, through its specialty pharmacy Onco360, has been selected as the national pharmacy partner for several newly approved therapies in the treatment of advanced cancers and rare genetic disorders. The therapies include GOMEKLI for neurofibromatosis type 1, AVMAPKI FAKZYNJA CO-PACK for recurrent low-grade serous ovarian cancer, and IBTROZI for ROS1-positive non-small cell lung cancer. Onco360 will provide access, education, data, and expert support for these innovative treatments.

BrightSpring Health Services, a leading provider of home- and community-based pharmacy and health solutions, has announced that its specialty pharmacy, Onco360, has been selected as the national pharmacy partner for several newly approved therapies in the treatment of advanced cancers and rare genetic disorders. The announcement was made on June 18, 2025, highlighting the company's commitment to expanding access to innovative treatments [1].

Onco360 will provide access, education, data, and expert support for the following newly approved therapies:

- GOMEKLI™ for neurofibromatosis type 1 (NF1), a rare genetic disorder that affects the nervous system. The medication is approved for adult and pediatric patients 2 years of age and older with symptomatic plexiform neurofibromas (PN) not amenable to complete resection [1].
- AVMAPKI™ FAKZYNJA™ CO-PACK for recurrent low-grade serous ovarian cancer (LGSOC). This therapy is approved for adult patients with KRAS-mutated recurrent LGSOC who have received prior systemic therapy [1].
- IBTROZI™ for ROS1-positive non-small cell lung cancer (NSCLC). The medication is approved for adult patients with locally advanced or metastatic ROS1-positive NSCLC [1].

BrightSpring President and CEO Jon Rousseau stated, "At Onco360, we continue to partner with innovators and manufacturers to deliver groundbreaking medicines and therapies to patients facing serious, life-threatening conditions, giving them additional hope" [1].

Onco360, a leading independent specialty pharmacy, dispenses nationally through its network of URAC- and ACHC-accredited Specialty Pharmacies. The company has been expanding its services and partnerships to provide comprehensive care and clinical solutions in all 50 states to over 400,000 customers, clients, and patients daily [1].

References:
[1] https://www.tradingview.com/news/reuters.com,2025-06-18:newsml_GNX8ZLsnr:0-brightspring-health-services-announces-onco360-selected-as-national-pharmacy-partner-for-multiple-new-cancer-and-rare-disease-drugs/